Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of BL-M07D1 in HER2-overexpressing or HER2-mutant advanced non-small cell lung cancer
CTR20233464Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Apr 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BL-M07D1 in non-small cell lung cancer (NSCLC), sponsored by Biokin Pharmaceutical. Started Apr 2024; status: active.
02
Drugs
BL-M07D1
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20233464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233464.